Blood Res.  2020 Jul;55(S1):S43-S53. 10.5045/br.2020.S008.

Treatment of relapsed and refractory multiple myeloma

• Lee JH
• Kim SH

• KMID: 2504742
• DOI: http://doi.org/10.5045/br.2020.S008

Abstract

The therapeutic strategy for relapsed and refractory multiple myeloma (RRMM) integrates a holistic approach regarding patient, disease, and drug-related factors. Patient-related factors include age, frailty status, and underlying comorbidities, especially cardiovascular and renal diseases and peripheral neuropathies that affect tolerability to multiple drug combinations or transplantations. Disease-related factors encompass these multiple patient-related factors, particularly the aggressiveness of the disease and cytogenetics. Regarding drug-related factors, the approval of novel proteasome inhibitors (such as carfilzomib and ixazomib), immunomodulatory agents (such as pomalidomide), monoclonal antibodies (such as daratumumab and elotuzumab), and new classes of drugs increasingly makes the choice treatment more complex and necessitates a comprehensive summary and an update of the efficacy and toxicities of each antimyeloma drug and its combinations. Further, careful monitoring of the side effects and supportive care throughout the course of treatment are important to achieve better outcomes for patients with RRMM.

Keyword

Relapsed and refractory; Multiple myeloma; Treatment

Figure

• 

  Fig. 1 Proposed treatment algorithm in relapsed and refractory multiple myeloma patients. Abbreviations: DRd, daratumumab-Rd; DVd, daratumumab-Vd; ERd, elotuzumab-Rd; IMiD, immunomodulatory drug; IMWG, international myeloma working group; IRd, ixazomib-Rd; Kd, carfilzomibdexamethasone; KRd, carfilzomib-Rd; LDH, lactate dehydrogenase; M protein, monoclonal protein; PCd, pomalidomide-cyclophosphamide, dexamethasone; Pd, pomalidomide, dexamethasone; PI, proteasome inhibitor; Rd, lenalidomide-low-dose dexamethasone; Vd, bortezomibdexamethasone.

Reference

1. Kumar SK, Dimopoulos MA, Kastritis E, et al. 2017; Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 31:2443–8. DOI: 10.1038/leu.2017.138. PMID: 28620163.

2. Anderson KC, Kyle RA, Rajkumar SV, et al. 2008; Clinically relevant end points and new drug approvals for myeloma. Leukemia. 22:231–9. DOI: 10.1038/sj.leu.2405016. PMID: 17972944.

3. Kumar S, Paiva B, Anderson KC, et al. 2016; International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17:e328–46.

4. Laubach J, Garderet L, Mahindra A, et al. 2016; Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 30:1005–17. DOI: 10.1038/leu.2015.356. PMID: 26710887.

5. Sonneveld P. 2017; Management of multiple myeloma in the relapsed/refractory patient. Hematology Am Soc Hematol Educ Program. 2017:508–17. DOI: 10.1182/asheducation-2017.1.508. PMID: 29222299. PMCID: PMC6142583.

6. Kumar SK, Dispenzieri A, Lacy MQ, et al. 2014; Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 28:1122–8. DOI: 10.1038/leu.2013.313. PMID: 24157580. PMCID: PMC4000285.

7. Salazar AS, Recinos LM, Mian HS, et al. 2019; Geriatric assessment and frailty scores predict mortality in myeloma: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 19:488–96.e6. DOI: 10.1016/j.clml.2019.04.014. PMID: 31133527.

8. Palumbo A, Bringhen S, Mateos MV, et al. 2015; Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 125:2068–74. DOI: 10.1182/blood-2014-12-615187. PMID: 25628469. PMCID: PMC4375104.

9. Lee JH, Kim SH, Huh SJ, et al. 2018; The survival of transplant ineligible multiple myeloma patients treated with bortezomib-based chemotherapy is affected by the patient fitness. Blood (ASH Annual Meeting Abstracts). 132(Suppl):3307. DOI: 10.1182/blood-2018-99-119473.

10. Lenhoff S, Hjorth M, Turesson I, et al. 2006; Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica. 91:1228–33.

11. Rasche L, Bernard C, Topp MS, et al. 2012; Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol. 91:1031–7. DOI: 10.1007/s00277-012-1414-5. PMID: 22286070.

12. Lee H, Duggan P, Chaudhry A, et al. 2018; Early relapse for multiple myeloma patients undergoing single autologous stem cell therapy: a single-center experience. Clin Lymphoma Myeloma Leuk. 18:e69–75. DOI: 10.1016/j.clml.2017.10.009. PMID: 29158114.

13. Gonsalves WI, Morice WG, Rajkumar V, et al. 2014; Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol. 167:500–5. DOI: 10.1111/bjh.13067. PMID: 25113422. PMCID: PMC4211997.

14. Sidiqi MH, Aljama MA, Jevremovic D, et al. 2019; Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplant. 54:442–7. DOI: 10.1038/s41409-018-0280-8. PMID: 30087461.

15. Offidani M, Boccadoro M, Di Raimondo F, Petrucci MT, Tosi P, Cavo M. 2019; Expert panel consensus statement for proper evaluation of first relapse in multiple myeloma. Curr Hematol Malig Rep. 14:187–96. DOI: 10.1007/s11899-019-00507-x. PMID: 31077067.

16. Avet-Loiseau H, Soulier J, Fermand JP, et al. 2010; Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leukemia. 24:623–8. DOI: 10.1038/leu.2009.273. PMID: 20072152.

17. Reece D, Song KW, Fu T, et al. 2009; Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 114:522–5. DOI: 10.1182/blood-2008-12-193458. PMID: 19332768.

18. Chng WJ, Goldschmidt H, Dimopoulos MA, et al. 2017; Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 31:1368–74. DOI: 10.1038/leu.2016.390. PMID: 28025582. PMCID: PMC5467042.

19. Moreau P, Masszi T, Grzasko N, et al. 2016; Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 374:1621–34. DOI: 10.1056/NEJMoa1516282. PMID: 27119237.

20. Palumbo A, Chanan-Khan A, Weisel K, et al. 2016; Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 375:754–66. DOI: 10.1056/NEJMoa1606038. PMID: 27557302.

21. Avet-Loiseau H, Fonseca R, Siegel D, et al. 2016; Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 128:1174–80. DOI: 10.1182/blood-2016-03-707596. PMID: 27439911. PMCID: PMC5009511.

22. Lonial S, Dimopoulos M, Palumbo A, et al. 2015; Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 373:621–31. DOI: 10.1056/NEJMoa1505654. PMID: 26035255.

23. Dimopoulos MA, Oriol A, Nahi H, et al. 2016; Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 375:1319–31. DOI: 10.1056/NEJMoa1607751. PMID: 27705267.

24. Moreau P, Siegel DS, Goldschmidt H, et al. 2018; Subgroup analysis of patients with biochemical or symptomatic relapse at the time of enrollment in the endeavor study. Blood (ASH Annual Meeting Abstracts). 132(Suppl):3243. DOI: 10.1182/blood-2018-99-112571.

25. Hulin C, de la Rubia J, Dimopoulos MA, et al. 2018; Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice. Health Sci Rep. 2:e104. DOI: 10.1002/hsr2.104. PMID: 30697597. PMCID: PMC6346989.

26. Madan S, Lacy MQ, Dispenzieri A, et al. 2011; Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood. 118:1763–5. DOI: 10.1182/blood-2011-04-350009. PMID: 21673347. PMCID: PMC3158710.

27. Richardson PG, Sonneveld P, Schuster MW, et al. 2005; Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 352:2487–98. DOI: 10.1056/NEJMoa043445. PMID: 15958804.

28. Koh Y, Lee SY, Kim I, et al. 2014; Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. Cancer Chemother Pharmacol. 74:653–7. DOI: 10.1007/s00280-014-2555-0. PMID: 25096796.

29. Palumbo A, Bringhen S, Ludwig H, et al. 2011; Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 118:4519–29. DOI: 10.1182/blood-2011-06-358812. PMID: 21841166.

30. Orlowski RZ, Nagler A, Sonneveld P, et al. 2007; Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 25:3892–901. DOI: 10.1200/JCO.2006.10.5460. PMID: 17679727.

31. Garderet L, Iacobelli S, Moreau P, et al. 2012; Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 30:2475–82. DOI: 10.1200/JCO.2011.37.4918. PMID: 22585692.

32. Hájek R, Masszi T, Petrucci MT, et al. 2017; A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 31:107–14. DOI: 10.1038/leu.2016.176. PMID: 27416912. PMCID: PMC5220126.

33. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. 2015; Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 372:142–52. DOI: 10.1056/NEJMoa1411321. PMID: 25482145.

34. Siegel DS, Dimopoulos MA, Ludwig H, et al. 2018; Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 36:728–34. DOI: 10.1200/JCO.2017.76.5032. PMID: 29341834.

35. Dimopoulos MA, Stewart AK, Masszi T, et al. 2017; Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 177:404–13. DOI: 10.1111/bjh.14549. PMID: 28211560. PMCID: PMC5412871.

36. Dimopoulos MA, Moreau P, Palumbo A, et al. 2016; Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 17:27–38. DOI: 10.1016/S1470-2045(15)00464-7. PMID: 26671818.

37. Moreau P, Mateos MV, Berenson JR, et al. 2018; Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3. study. Lancet Oncol. 19:953–64. DOI: 10.1016/S1470-2045(18)30354-1.

38. Dimopoulos MA, Moreau P, Iida S, et al. 2019; Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. Int J Hematol. 110:466–73. DOI: 10.1007/s12185-019-02704-z. PMID: 31388932.

39. Ghobrial IM, Vij R, Siegel D, et al. 2019; A phase Ib/II study of oprozomib in patients with advanced multiple myeloma and Waldenström macroglobulinemia. Clin Cancer Res. 25:4907–16. DOI: 10.1158/1078-0432.CCR-18-3728. PMID: 31142508.

40. Shah J, Usmani S, Stadtmauer EA, et al. 2019; Oprozomib, pomalidomide, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 19:570–8.e1. DOI: 10.1016/j.clml.2019.05.017. PMID: 31326409.

41. Harrison SJ, Mainwaring P, Price T, et al. 2016; Phase I clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052-102 final results. Clin Cancer Res. 22:4559–66. DOI: 10.1158/1078-0432.CCR-15-2616. PMID: 27117181.

42. Kwon J, Min CK, Kim K, et al. 2017; Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. Cancer Med. 6:100–8. DOI: 10.1002/cam4.970. PMID: 27905203. PMCID: PMC5269709.

43. Dimopoulos MA, Chen C, Spencer A, et al. 2009; Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 23:2147–52. DOI: 10.1038/leu.2009.147. PMID: 19626046.

44. Dimopoulos MA, Palumbo A, Attal M, et al. 2011; Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia. 25:749–60. DOI: 10.1038/leu.2011.3. PMID: 21293488.

45. Kim K, Kim SJ, Voelter V, et al. 2014; Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients. Ann Hematol. 93:113–21. DOI: 10.1007/s00277-013-1893-z. PMID: 24026427.

46. Richardson PG, Xie W, Jagannath S, et al. 2014; A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 123:1461–9. DOI: 10.1182/blood-2013-07-517276. PMID: 24429336. PMCID: PMC4123434.

47. Miguel JS, Weisel K, Moreau P, et al. 2013; Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 14:1055–66. DOI: 10.1016/S1470-2045(13)70380-2. PMID: 24007748.

48. Leleu X, Karlin L, Macro M, et al. 2015; Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood. 125:1411–7. DOI: 10.1182/blood-2014-11-612069. PMID: 25575538.

49. Baz RC, Martin TG 3rd, Lin HY, et al. 2016; Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 127:2561–8. DOI: 10.1182/blood-2015-11-682518. PMID: 26932802.

50. Lee JH, Kim SH, Lee YJ, et al. 2019; The comparison of carfilzomib, and dexamethasone versus pomalidomide-based combination chemotherapy after a 2nd-line therapy in relapsed and refractory multiple myeloma patients. Clin Lymphoma Myeloma Leuk (International Myeloma Workshop Abstracts). 19(Suppl):e264–5. DOI: 10.1016/j.clml.2019.09.437.

51. Richardson PG, Oriol A, Beksac M, et al. 2019; Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 20:781–94. DOI: 10.1016/S1470-2045(19)30152-4. PMID: 31097405.

52. Lokhorst HM, Plesner T, Laubach JP, et al. 2015; Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 373:1207–19. DOI: 10.1056/NEJMoa1506348. PMID: 26308596.

53. Lonial S, Weiss BM, Usmani SZ, et al. 2016; Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 387:1551–60. DOI: 10.1016/S0140-6736(15)01120-4. PMID: 26778538.

54. Usmani SZ, Weiss BM, Plesner T, et al. 2016; Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 128:37–44. DOI: 10.1182/blood-2016-03-705210. PMID: 27216216. PMCID: PMC4937359.

55. Usmani SZ, Nahi H, Weiss BM, et al. 2017; Safety and efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed and refractory multiple myeloma: final results from GEN501 and SIRIUS. Blood (ASH Annual Meeting Abstracts). 130(Suppl):3107.

56. Park SS, Eom HS, Kim JS, et al. 2019; Brief report: clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. Jpn J Clin Oncol. 49:92–5. DOI: 10.1093/jjco/hyy177. PMID: 30476124.

57. Byun JM, Yoon SS, Koh Y, et al. 2019; Daratumumab monotherapy in heavily pretreated Asian patients with relapsed and refractory multiple myeloma: a real-world experience. Anticancer Res. 39:5165–70. DOI: 10.21873/anticanres.13712. PMID: 31519629.

58. Dimopoulos MA, San-Miguel J, Belch A, et al. 2018; Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 103:2088–96. DOI: 10.3324/haematol.2018.194282. PMID: 30237262. PMCID: PMC6269302.

59. Spencer A, Lentzsch S, Weisel K, et al. 2018; Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 103:2079–87. DOI: 10.3324/haematol.2018.194118. PMID: 30237264. PMCID: PMC6269293.

60. San-Miguel J, Weisel K, Cook G, et al. 2017; Efficacy by cytogenetic risk status for daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone in relapsed or refractory multiple myeloma. Haematologica. 102:1–2.

61. Zonder JA, Mohrbacher AF, Singhal S, et al. 2012; A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 120:552–9. DOI: 10.1182/blood-2011-06-360552. PMID: 22184404. PMCID: PMC4467882.

62. Lonial S, Dimopoulos MA, Weisel K, et al. 2018; Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab+ lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM). J Clin Oncol (ASCO Annual Meeting Abstracts). 36(Suppl):8040.

63. Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. 2007; The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica. 92:1149–50. DOI: 10.3324/haematol.11228. PMID: 17650451.

64. Kumar SK, Grzasko N, Delimpasi S, et al. 2019; Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. Br J Haematol. 184:536–46. DOI: 10.1111/bjh.15679. PMID: 30460684.

65. Case DC Jr, Young CW, Lee BJ 3rd. 1977; Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine and vinblastine (ABDV). Cancer. 39:1382–6. DOI: 10.1002/1097-0142(197704)39:4<1382::AID-CNCR2820390405>3.0.CO;2-F. PMID: 66972.

66. Park S, Lee SJ, Jung CW, et al. 2014; DCEP for relapsed or refractory multiple myeloma after therapy with novel agents. Ann Hematol. 93:99–105. DOI: 10.1007/s00277-013-1952-5. PMID: 24240976.

67. Lee CK, Barlogie B, Munshi N, et al. 2003; DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 21:2732–9. DOI: 10.1200/JCO.2003.01.055. PMID: 12860952.

68. Lakshman A, Singh PP, Rajkumar SV, et al. 2018; Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol. 93:179–86. DOI: 10.1002/ajh.24954. PMID: 29067723.

69. Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H. 2005; The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica. 90:1287–8. PMID: 16154860.

70. Kim SJ, Bang SM, Choi YS, et al. 2016; Bendamustine in heavily pre-treated multiple myeloma patients: results of a retrospective analysis from the Korean Multiple Myeloma Working Party. Blood Res. 51:193–9. DOI: 10.5045/br.2016.51.3.193. PMID: 27722131. PMCID: PMC5054252.

71. Lentzsch S, O'Sullivan A, Kennedy RC, et al. 2012; Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 119:4608–13. DOI: 10.1182/blood-2011-12-395715. PMID: 22451423. PMCID: PMC3392072.

72. Offidani M, Corvatta L, Maracci L, et al. 2013; Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J. 3:e162. DOI: 10.1038/bcj.2013.58. PMID: 24270324. PMCID: PMC3880441.

73. San-Miguel JF, Hungria VT, Yoon SS, et al. 2014; Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 15:1195–206. DOI: 10.1016/S1470-2045(14)70440-1. PMID: 25242045.

74. Chari A, Vogl DT, Gavriatopoulou M, et al. 2019; Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 381:727–38. DOI: 10.1056/NEJMoa1903455. PMID: 31433920.

75. Giralt S, Garderet L, Durie B, et al. 2015; American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 21:2039–51. DOI: 10.1016/j.bbmt.2015.09.016. PMID: 26428082. PMCID: PMC4757494.

76. Sellner L, Heiss C, Benner A, et al. 2013; Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer. 119:2438–46. DOI: 10.1002/cncr.28104. PMID: 23576287.

77. Cook G, Ashcroft AJ, Cairns DA, et al. 2016; The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 3:e340–51. DOI: 10.1016/S2352-3026(16)30049-7. PMID: 27374467.

78. Yhim HY, Kim K, Kim JS, et al. 2013; Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT. Bone Marrow Transplant. 48:425–32. DOI: 10.1038/bmt.2012.164. PMID: 22941384.

79. Goldschmidt H, Baertsch MA, Schlenzka J, et al. 2018; Salvage autologous transplant and lenalidomide maintenance versus continuous lenalidomide/dexamethasone for relapsed multiple myeloma: results of the randomized GMMG phase III multicenter trial relapse. Blood (ASH Annual Meeting Abstracts). 132(Suppl):253. DOI: 10.1182/blood-2018-99-111203.

80. Crawley C, Lalancette M, Szydlo R, et al. 2005; Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 105:4532–9. DOI: 10.1182/blood-2004-06-2387. PMID: 15731182.

81. Ikeda T, Mori K, Kawamura K, et al. 2019; Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. Hematol Oncol. 37:586–94. DOI: 10.1002/hon.2688. PMID: 31674032.